• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, September 18, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

BioIVT introduces high-purity Kupffer cells to support drug discovery and development for liver diseases and help predict adverse drug reactions

Bioengineer by Bioengineer
May 11, 2020
in Health
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Dysregulation of the Kupffer cell response contributes to liver diseases such as nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and liver fibrosis

IMAGE

Credit: BioIVT

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is adding high-purity Kupffer cells to its portfolio of human primary hepatic cells to support liver disease drug discovery and development and help predict adverse drug reactions.

Kupffer cells perform a scavenger role in the liver, removing small particles, senescent cells and cell debris. They also play an important role in the immune response to liver pathogens. Dysregulation of the Kupffer cell response contributes to chronic inflammation, leading to liver diseases such as nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and liver fibrosis. NASH is a type of NAFLD, which also includes liver inflammation and liver cell damage.1

BioIVT is already a leading provider of Kupffer-enriched non-parenchymal cells (NPCs); researchers use these cells in a variety of plated monocultures, co-cultures and liver microtissue configurations. As researchers are increasingly interested in evaluating the effects of Kupffer cells in predictive models, BioIVT developed the high purity product to provide them with additional options. High-purity Kupffer cells will be sold in vials containing a minimum of one million viable cells.

“Our staff’s technical expertise has enabled us to isolate high-purity Kupffer cells,” said BioIVT Senior Vice President, ADME-Tox Dr. Chris Black. “We now offer this valuable resource as a catalog product to drug discovery and development researchers for use in a variety of in-vitro and disease models, including mechanistic and screening assays, toxicity models, and for predicting inflammation-induced adverse drug reactions.”

BioIVT’s Kupffer cells complement its portfolio of biospecimens for NASH and NAFLD models, including human hepatocytes with a NAFLD activity score (NAS), peripheral blood mononuclear cells (PBMCs), and other biofluids from donors with clinically defined NASH. To further support researchers in this field, BioIVT also sells the requisite media.

To isolate high-purity Kupffer cells, BioIVT uses an affinity purification method based on cell surface markers that preferentially attach to magnetic beads. Cell purity is assessed by CD68 positivity using flow cytometry. Cell function is assessed based on Interleukin 6 (IL-6) release in response to lipopolysaccharide (LPS) and phagocytosis of fluorescent latex beads.

###

Additional information about BioIVT’s Kupffer cells and related products and services can be found at https://bioivt.com/kupffer-cells.

BioIVT will also be covering “Kupffer Cells: Methods & Applications” as part of its “Chalk Talk” webinar series. Research Scientist Karissa Cottier, PhD, will lead the session at 11 a.m. ET on May 29. Researchers who would like to participate can register here.

Reference

1. https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/definition-facts

About BioIVT

BioIVT is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO® Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the premier supplier of hepatic products, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit http://www.bioivt.com or follow the company on Twitter @BioIVT.

Media Contact
Lisa Osborne
[email protected]

Tags: Internal MedicineLiverMedicine/HealthPharmaceutical ScienceResearch/Development
Share12Tweet8Share2ShareShareShare2

Related Posts

Revolutionizing Cancer Care: Understanding Patient Fatigue

September 18, 2025

Factors Influencing Outcomes in Low Back Pain Treatment

September 18, 2025

UTHealth Houston Researchers Receive $27 Million to Lead National Alzheimer’s Data Network Harnessing Real-World Data

September 18, 2025

1 in 3 young adults avoid the dentist — why it matters for your health

September 18, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    155 shares
    Share 62 Tweet 39
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    117 shares
    Share 47 Tweet 29
  • Physicists Develop Visible Time Crystal for the First Time

    67 shares
    Share 27 Tweet 17
  • Tailored Gene-Editing Technology Emerges as a Promising Treatment for Fatal Pediatric Diseases

    49 shares
    Share 20 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Revolutionizing Cancer Care: Understanding Patient Fatigue

Meteorological Influences on Cotton Pest Dynamics in India

Factors Influencing Outcomes in Low Back Pain Treatment

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.